777 related articles for article (PubMed ID: 33625411)
1. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
[TBL] [Abstract][Full Text] [Related]
2. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
Zins K; Abraham D
Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
[TBL] [Abstract][Full Text] [Related]
3. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
5. Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages.
Ovais M; Guo M; Chen C
Adv Mater; 2019 May; 31(19):e1808303. PubMed ID: 30883982
[TBL] [Abstract][Full Text] [Related]
6. TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress.
Shen X; Zhou S; Yang Y; Hong T; Xiang Z; Zhao J; Zhu C; Zeng L; Zhang L
Front Oncol; 2022; 12():1034842. PubMed ID: 36419877
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
8. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
Wei X; Wang J; Liang M; Song M
Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
10. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.
Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB
Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284
[TBL] [Abstract][Full Text] [Related]
12. Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.
He Y; de Araújo Júnior RF; Cruz LJ; Eich C
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683963
[TBL] [Abstract][Full Text] [Related]
13. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines.
Cheng Y; Song S; Wu P; Lyu B; Qin M; Sun Y; Sun A; Mu L; Xu F; Zhang L; Wang J; Zhang Q
Adv Healthc Mater; 2021 Sep; 10(18):e2100590. PubMed ID: 34292673
[TBL] [Abstract][Full Text] [Related]
14. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
15. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
Xu L; Xie X; Luo Y
Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
[TBL] [Abstract][Full Text] [Related]
16. Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy.
Li SL; Hou HY; Chu X; Zhu YY; Zhang YJ; Duan MD; Liu J; Liu Y
ACS Nano; 2024 Mar; 18(11):7769-7795. PubMed ID: 38420949
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy.
Khan SU; Khan MU; Azhar Ud Din M; Khan IM; Khan MI; Bungau S; Hassan SSU
Front Immunol; 2023; 14():1166487. PubMed ID: 37138860
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
